Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis-Reference-Cited by-同舟云学术

Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis

Published:2017-05-08 Issue:3 Volume:47 Page:248-250
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Kono M¹,Yasuda S¹,Kono M¹,Atsumi T¹

Affiliation:

1. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2017.1297482

Reference10 articles.

1. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A

2. The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis

3. Treatment of systemic sclerosis with tocilizumab

4. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

5. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial;Modern Rheumatology;2023-07-04

2. Systemic sclerosis and rheumatoid arthritis overlap syndrome – management of severe cardiac, pulmonary and articular involvement;Rheumatology;2023-03-08

3. Tocilizumab and its usage for skin diseases;Italian Journal of Dermatology and Venereology;2022-02

4. Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis;Biomedicines;2022-01-29

5. Is biological therapy in systemic sclerosis the answer?;Rheumatology International;2020-01-20